HK1243709A1 - 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物 - Google Patents

可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物

Info

Publication number
HK1243709A1
HK1243709A1 HK18103304.5A HK18103304A HK1243709A1 HK 1243709 A1 HK1243709 A1 HK 1243709A1 HK 18103304 A HK18103304 A HK 18103304A HK 1243709 A1 HK1243709 A1 HK 1243709A1
Authority
HK
Hong Kong
Prior art keywords
aminohydrothiazine
tetrahydrofurane
alzheimer
fused
disease
Prior art date
Application number
HK18103304.5A
Other languages
English (en)
Inventor
David Michael Remick
Simon James Richards
Adam Jan Sanderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1243709A1 publication Critical patent/HK1243709A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C07C309/31—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups by alkyl groups containing at least three carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
HK18103304.5A 2015-04-29 2018-03-08 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物 HK1243709A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154242P 2015-04-29 2015-04-29
PCT/US2016/028896 WO2016176118A1 (en) 2015-04-29 2016-04-22 Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
HK1243709A1 true HK1243709A1 (zh) 2018-07-20

Family

ID=55861291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103304.5A HK1243709A1 (zh) 2015-04-29 2018-03-08 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物

Country Status (40)

Country Link
US (1) US10011610B2 (zh)
EP (1) EP3288949B1 (zh)
JP (2) JP2017515831A (zh)
KR (1) KR101979534B1 (zh)
CN (1) CN107531728B (zh)
AR (1) AR104241A1 (zh)
AU (1) AU2016254980B2 (zh)
BR (1) BR112017020180A2 (zh)
CA (1) CA2981091A1 (zh)
CL (1) CL2017002651A1 (zh)
CO (1) CO2017010725A2 (zh)
CR (1) CR20170433A (zh)
CY (1) CY1122375T1 (zh)
DK (1) DK3288949T3 (zh)
DO (1) DOP2017000240A (zh)
EA (1) EA032293B1 (zh)
EC (1) ECSP17071769A (zh)
ES (1) ES2765646T3 (zh)
GT (1) GT201700227A (zh)
HK (1) HK1243709A1 (zh)
HR (1) HRP20192237T1 (zh)
HU (1) HUE047160T2 (zh)
IL (1) IL254252A0 (zh)
MA (1) MA41975B1 (zh)
MD (1) MD3288949T2 (zh)
ME (1) ME03660B (zh)
MX (1) MX2017013694A (zh)
MY (1) MY180727A (zh)
NZ (1) NZ735249A (zh)
PE (1) PE20180048A1 (zh)
PH (1) PH12017501955A1 (zh)
PL (1) PL3288949T3 (zh)
PT (1) PT3288949T (zh)
RS (1) RS59729B1 (zh)
SG (1) SG11201708003WA (zh)
SI (1) SI3288949T1 (zh)
SV (1) SV2017005547A (zh)
TN (1) TN2017000448A1 (zh)
TW (1) TWI619719B (zh)
WO (1) WO2016176118A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
US11559528B2 (en) * 2019-09-05 2023-01-24 The Cleveland Clinic Foundation BACE1 inhibition for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
CA2711655C (en) * 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
CN102171221B (zh) 2008-09-30 2013-11-06 卫材R&D管理有限公司 新的稠合的氨基二氢噻嗪衍生物
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2703401A4 (en) * 2011-04-26 2014-12-03 Shionogi & Co PYRIDINE DERIVATIVE AND BACE-1 HEMMER THEREOF
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
JP2014101354A (ja) * 2012-10-24 2014-06-05 Shionogi & Co Ltd Ｂａｃｅ１阻害作用を有するオキサジン誘導体
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TWI675034B (zh) 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
US20210355138A1 (en) 2016-08-11 2021-11-18 Eli Lilly And Company Aminothiazinies and their use as bace1 inhibitors

Also Published As

Publication number Publication date
TN2017000448A1 (en) 2019-04-12
CN107531728A (zh) 2018-01-02
ECSP17071769A (es) 2018-02-28
KR20170131597A (ko) 2017-11-29
HUE047160T2 (hu) 2020-04-28
GT201700227A (es) 2018-11-23
CN107531728B (zh) 2019-11-19
TWI619719B (zh) 2018-04-01
NZ735249A (en) 2018-08-31
AU2016254980B2 (en) 2018-06-21
RS59729B1 (sr) 2020-02-28
US10011610B2 (en) 2018-07-03
EP3288949B1 (en) 2019-11-06
HRP20192237T1 (hr) 2020-03-06
EP3288949A1 (en) 2018-03-07
PT3288949T (pt) 2020-01-16
TW201710268A (zh) 2017-03-16
PL3288949T3 (pl) 2020-06-01
CO2017010725A2 (es) 2018-01-31
ES2765646T3 (es) 2020-06-10
CY1122375T1 (el) 2021-01-27
DK3288949T3 (da) 2020-01-13
IL254252A0 (en) 2017-10-31
JP2017515831A (ja) 2017-06-15
MX2017013694A (es) 2018-03-02
EA201792109A1 (ru) 2018-03-30
EA032293B1 (ru) 2019-05-31
BR112017020180A2 (pt) 2018-06-12
AU2016254980A1 (en) 2017-09-21
CR20170433A (es) 2017-11-07
JP2018140987A (ja) 2018-09-13
JP6777668B2 (ja) 2020-10-28
SV2017005547A (es) 2018-04-24
MY180727A (en) 2020-12-08
SG11201708003WA (en) 2017-10-30
ME03660B (me) 2020-07-20
PE20180048A1 (es) 2018-01-15
DOP2017000240A (es) 2017-11-15
WO2016176118A1 (en) 2016-11-03
US20160318953A1 (en) 2016-11-03
MA41975B1 (fr) 2020-01-31
CL2017002651A1 (es) 2018-04-20
PH12017501955A1 (en) 2018-03-19
MD3288949T2 (ro) 2020-03-31
KR101979534B1 (ko) 2019-05-16
AR104241A1 (es) 2017-07-05
CA2981091A1 (en) 2016-11-03
SI3288949T1 (sl) 2019-12-31

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating Alzheimer&#39;s disease
ZA201605341B (en) Methods of treating alzheimer&#39;s disease
IL247085B (en) Methods for treating Alzheimer&#39;s disease
IL263433A (en) Methods for treating Alzheimer&#39;s disease
EP3268086A4 (en) Lsd for the treatment of alzheimer&#39;s disease
IL263188B (en) Treatment for Parkinson&#39;s disease
HK1243709A1 (zh) 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
SI3413870T1 (sl) Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer&#39;s disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson&#39;s disease
ZA201807944B (en) Treatment for parkinson&#39;s disease
HK1245081A1 (zh) 用於治療阿爾茨海默病的方法
GB201511453D0 (en) Treatment of alzheimer&#39;s disease
GB201614863D0 (en) Alzheimer&#39;s disease
AU2015904411A0 (en) Compositions and methods for the treatment of Alzheimer&#39;s disease
GB201518052D0 (en) Parkinson&#39;s disease treatment
SG11201607693WA (en) 6-substituted estradiol derivatives for the treatment of alzheimer&#39;s disease
GB201504144D0 (en) Treatment of Parkinson&#39;s disease
GB201414038D0 (en) Alzheimer&#39;s disease